---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023080"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:41:44.023375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track

## Summary
- Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.
- R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.
- Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.
- X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.
- End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024.

## SEC filing metadata
- accession: 0000950170-24-023080
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/0000950170-24-023080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/xene-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023080
- JSON: https://secwatch.observer/filing/0000950170-24-023080.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023080.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017024023080/0000950170-24-023080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.